Cytori Therapeutics, Inc. (CYTX) Reports In-Line Q1 Loss of 14c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Roth Keeps Cytori Therapeutics (CYTX) at 'Buy'; Still Encouraged by Streamlining Efforts
May 13, 2014 9:20 AM EDTRoth Capital affirms Cytori Therapeutics (Nasdaq: CYTX) at Buy with a price target of $10 following Q1 results.
Analyst Joseph Pantginis noted that Cytori posted Q1 loss of $.14 per share, flat with consensus views. Revs of $1.43 million compared with the firm's expectation for $2.7 million.
Pantginis commented, We are encouraged by Cytori's continued streamlining of efforts based on three main fronts, 1) managerial, 2) commercial and, importantly, 3) clinical progress. Primary focus is... More
Cytori Therapeutics (CYTX) Files $100M Mixed Shelf
May 12, 2014 8:00 AM EDTCytori Therapeutics, Inc. (Nasdaq: CYTX) filed a regisration with the U.S. SEC to sell, from time to time, up to $100 million of , Common Stock, Preferred Stock, Debt Securities, Warrants, Units, or any combination thereof.
... More